Search results for "International Normalized Ratio"

showing 8 items of 18 documents

International Normalized Ratio and Mortality Risk in Acute Heart Failure and Nonvalvular Atrial Fibrillation Patients Receiving Vitamin K Antagonists

2019

Introduction and objectives: Heart failure patients with nonvalvular atrial fibrillation (NVAF) on treatment with vitamin K antagonists (VKA) often have suboptimal international normalized ratio (INR) values. Our aim was to evaluate the association between INR values at admission due to acute heart failure and mortality risk during follow-up. Methods: In this observational study, we retrospectively assessed INR on admission in 1137 consecutive patients with acute heart failure and NVAF who were receiving VKA treatment. INR was categorized into optimal values (INR = 2-3, n = 210), subtherapeutic (INR 3, n = 267). Because INR did not meet the proportional hazards assumption for mortality, res…

Maleendocrine systemmedicine.medical_specialtyTime FactorsVitamin KHeart failure030204 cardiovascular system & hematologyVitamin kRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInterquartile rangeCause of DeathThromboembolismhealth services administrationMean Survival TimeInternal medicineAtrial FibrillationmedicineHumansheterocyclic compoundsInternational Normalized Ratiocardiovascular diseasesInternational normalized ratioNormal rangeAgedRetrospective StudiesHeart Failurebusiness.industryIncidencefungiAnticoagulantsAtrial fibrillationGeneral MedicinePrognosismedicine.diseaseAtrial fibrillationSurvival RateSpainHeart failureAcute DiseaseCardiologyFemaleObservational studybusinessFollow-Up StudiesRevista Española de Cardiología (English Edition)
researchProduct

Relevance of depression for anticoagulation management in a routine medical care setting: results from the ThrombEVAL study program

2014

Summary Background Depressive symptoms have detrimental effects on quality of life and mortality. Poor adherence to a treatment regimen is a potential mechanism for the increased risk of adverse medical events associated with depression. Regarding oral anticoagulation with vitamin K antagonists, adherence is crucial for the outcome. Little is known about the clinical relevance of current depressiveness for anticoagulation treatment. Objectives To examine the impact of current depressiveness on anticoagulation treatment in regular medical care. Patients/Methods We examined the association between clinically significant depressiveness as assessed by the Patient Health Questionnaire-2 ≥ 2 (PHQ…

Malemedicine.medical_specialtyCross-sectional studyAdministration OralHealth literacyMedication AdherenceCohort StudiesPatient satisfactionQuality of lifeAmbulatory careSurveys and QuestionnairesInternal medicineAmbulatory CarePrevalenceHumansMedicineClinical significanceInternational Normalized RatioDepression (differential diagnoses)AgedDepressionbusiness.industryAnticoagulantsHematologyMiddle AgedCross-Sectional StudiesTreatment OutcomePatient SatisfactionMultivariate AnalysisPhenprocoumonQuality of LifePhysical therapyFemalebusinessCohort studyJournal of Thrombosis and Haemostasis
researchProduct

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: A randomized trial

2009

BACKGROUND: Low-dose oral vitamin K decreases the international normalized ratio (INR) in overanticoagulated patients who receive warfarin therapy. Its effects on bleeding events are uncertain. OBJECTIVE: To see whether low-dose oral vitamin K reduces bleeding events over 90 days in patients with warfarin-associated coagulopathy. DESIGN: Multicenter, randomized, placebo-controlled trial. Randomization was computer-generated, and participants were allocated to trial groups by using sequentially numbered study drug containers. Patients, caregivers, and those who assessed outcomes were blinded to treatment assignment. SETTING: 14 anticoagulant therapy clinics in Canada, the United States, and …

Malemedicine.medical_specialtyRandomizationVitamin Kmedicine.drug_classAdministration OralHemorrhageoral vitamin k anticoagulantsPlacebolaw.inventionSettore MED/15 - Malattie Del SanguePlacebosRandomized controlled trialOral administrationlawInternal medicineThromboembolismInternal MedicinemedicineOutpatient clinicHumansInternational Normalized RatioAgedAged 80 and overbusiness.industryAnticoagulantWarfarinAge FactorsAnticoagulantsGeneral MedicineMiddle AgedAntifibrinolytic AgentsSurgeryClinical trialTreatment OutcomeFemaleWarfarinbusinessmedicine.drug
researchProduct

Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national…

2021

Abstract Aims Vitamin K antagonists (VKAs) are effective drugs reducing the risk for stroke in atrial fibrillation (AF), but the benefits derived from such therapy depend on the international normalized ratio (INR) maintenance in a narrow therapeutic range. Here, we aimed to determine independent variables driving poor anticoagulation control [defined as a time in therapeutic range (TTR) <65%] in a ‘real world’ national cohort of AF patients. Methods and results The SULTAN registry is a multicentre, prospective study, involving patients with non-valvular AF from 72 cardiology units expert in AF in Spain. At inclusion, all patients naïve for oral anticoagulation were started with VKAs…

Malemedicine.medical_specialtyVitamin K030204 cardiovascular system & hematologyAmiodaroneCoronary artery disease03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineAtrial FibrillationHumansMedicineInternational Normalized RatioProspective StudiesRegistries030212 general & internal medicineProspective cohort studyStrokeAgedAged 80 and overbusiness.industryProportional hazards modelAnticoagulantsAtrial fibrillationOdds ratioMiddle Agedmedicine.diseaseConfidence intervalStrokeFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEP Europace
researchProduct

Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists.

2018

BACKGROUND Although polypharmacy is associated with a negative clinical outcome in various settings and commonly observed in patients receiving oral anticoagulation therapy, evidence on the relevance for the clinical outcome of anticoagulated patients is currently limited. The aim of the study was to investigate the effect of polypharmacy on the clinical outcomes among patients taking phenprocoumon. DESIGN Prospective cohort study. SETTING Regular medical care. PARTICIPANTS Information on 2011 individuals receiving vitamin K antagonists was available for analysis from the prospective multicenter thrombEVAL study. MEASUREMENTS Data were obtained from clinical visits, computer-assisted interv…

Malemedicine.medical_specialtyVitamin KAdministration OralHemorrhage030204 cardiovascular system & hematologyPhenprocoumonCohort Studies03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineGermanyPrevalenceMedicineHumansCumulative incidenceDrug Interactions030212 general & internal medicineInternational Normalized RatioMultiple Chronic ConditionsProspective StudiesRisk factorMortalityProspective cohort studyAdverse effectAgedPolypharmacybusiness.industryMedical recordHazard ratioAnticoagulantsHospitalizationPolypharmacyFemaleGeriatrics and GerontologyDrug Monitoringbusinessmedicine.drugJournal of the American Geriatrics Society
researchProduct

Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10

2009

SummaryUnanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

Malemedicine.medical_specialtyVitamin Kmedicine.drug_classAdministration OralHemorrhagePharmacotherapyInternal medicinemedicineCoagulopathyHumansInternational Normalized RatioProspective StudiesProspective cohort studyAgedAged 80 and overVenous ThrombosisVascular diseasebusiness.industryAnticoagulantWarfarinAnticoagulantsHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryFemaleINR oral anticoagulantsWarfarinbusinessFollow-Up Studiesmedicine.drugCohort studyThrombosis and Haemostasis
researchProduct

Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease

2007

Abstract Background : Recent evidence suggests that duloxetine may increase the effect of warfarin, thereby increasing the possibility of bleeding. However, a MEDLINE search for articles published between 1980 and May 2007 (terms: duloxetine , anticoagulants , acenocoumarol , and interaction ; no language restriction) did not yield any reports of an interaction between concomitant use of duloxetine and acenocoumarol. Objective : The aim of this study was to describe a potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease. The possible mechanism of this potential interaction is examined. Case summary : This report presents the case of a 63…

medicine.drug_classThiophenesDuloxetine Hydrochloridechemistry.chemical_compoundAlzheimer DiseasemedicineHumansDuloxetineDrug InteractionsPharmacology (medical)International Normalized Ratioduloxetine acenocoumarol international normalized ratio Alzheimer’s diseasePharmacologyAcenocoumarolbusiness.industryAcenocoumarolAnticoagulantWarfarinAnticoagulantsMiddle AgedDrug interactionDiscontinuationchemistryAnesthesiaConcomitantFemaleSettore MED/26 - NeurologiabusinessReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugClinical Therapeutics
researchProduct

A score model for the continuous grading of early allograft dysfunction severity

2014

Early allograft dysfunction (EAD) dramatically influences graft and patient outcomes. A lack of consensus on an EAD definition hinders comparisons of liver transplant outcomes and management of recipients among and within centers. We sought to develop a model for the quantitative assessment of early allograft function [Model for Early Allograft Function Scoring (MEAF)] after transplantation. A retrospective study including 1026 consecutive liver transplants was performed for MEAF score development. Multivariate data analysis was used to select a small number of postoperative variables that adequately describe EAD. Then, the distribution of these variables was mathematically modeled to assig…

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentLiver transplantationModels BiologicalSeverity of Illness IndexDecision Support TechniquesLiver diseasePredictive Value of TestsRisk FactorsInternal medicineSeverity of illnessmedicineHumansInternational Normalized RatioBlood CoagulationProportional Hazards ModelsRetrospective StudiesPrincipal Component AnalysisTransplantationHepatologyProportional hazards modelbusiness.industryGraft SurvivalReproducibility of ResultsAlanine TransaminaseBayes TheoremBilirubinRetrospective cohort studyClinical Enzyme Testsmedicine.diseaseLiver TransplantationSurgeryTransplantationTreatment OutcomeNonlinear DynamicsPredictive value of testsMultivariate AnalysisSurgeryLiver functionPrimary Graft DysfunctionbusinessBiomarkersLiver Transplantation
researchProduct